Lilly/Avid Alzheimer's Diagnostic May Need To Broaden Target Population Before Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
While florbetapir F 18 injection showed good results in terminal patients, Avid Radiopharmaceuticals will have to convince an FDA advisory panel that it can be used to diagnose patients in the early stages of Alzheimer's disease or other dementias.